Background and objective: Although an association between pulmonary tuberculosis (TB) and chronic obstructive pulmonary disease (COPD) has been suggested, studies on the effect of TB in COPD patients have not been conducted. We aimed to investigate the severity and clinical outcomes of COPD in patients with and without a history of TB. Methods: We retrospectively reviewed the data of 1784 patients with COPD in the Korean COPD Subtype Study cohort collected from December 2011 to January 2017 and followed up for 3 years. Results: Among the 1784 patients at baseline, the COPD assessment test (CAT) scores and total St George's Respiratory Questionnaire for COPD (SGRQc) scores were significantly higher in the prior TB group (n = 468) than in the non-TB group (n = 1316). Lung function and exacerbation prevalence were significantly poorer and higher, respectively, in the prior TB group than in the non-TB group. In a small-sized follow-up study, CAT scores (n = 318), SGRQc scores (n = 295) and lung function (n = 182) remained poorer, and exacerbation prevalence (n = 256) remained higher in the prior TB group over 3 years. The forced expiratory volume in 1 s in the prior TB group declined (−0.57%/year), whereas it improved (+0.93%/year) in the non-TB group (P for changes between the groups = 0.076). In the prior TB group, patients showed poorer lung function compared with the non-TB group regardless of having lung lesions visible or not on chest radiographs. Conclusion: TB history negatively affected the severity of COPD, and a small-sized follow-up study showed that the changes were sustained for several years.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is considered a serious health problem worldwide. COPD morbidity and mortality have been increasing because of ageing societies, increased smoking prevalence and air pollution, and lead to high health costs. [1] [2] [3] [4] [5] COPD is characterized by chronic inflammation induced by toxic particles and gases resulting in progressive and irreversible airway obstruction characterized by bronchitis and emphysema. Cigarette smoking and ageing are well-known major risk factors for the development of COPD. [6] [7] [8] [9] In addition, recent studies have reported that biomass smoke, 10 the microbiome, 11 nutritional absorption, 12 mitochondrial damage 13 and even genetic factors 14 contribute to and/or aggravate COPD.
SUMMARY AT A GLANCE
We demonstrated that chronic obstructive pulmonary disease (COPD) patients with a history of tuberculosis (TB) had more severe symptoms, poorer lung function and more frequent exacerbations. The differences were sustained for 3 years compared with those with no TB history.
Pulmonary tuberculosis (TB) was suggested to be one of the causes of COPD in the 1950s. 15 The Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) study in 2007 showed that a history of TB was significantly associated with airflow obstruction. 16 Moreover, a large Chinese cohort study revealed that TB was an independent risk factor for airflow obstruction. 17 Health insurance databases in Taiwan showed the same results and demonstrated that the prompt initiation of anti-TB treatment may prevent COPD. A recent Korean study showed that subjects with a TB history without sequelae on chest imaging were vulnerable to pulmonary function impairment and respiratory symptoms. 18 While an association between TB and COPD has been reported in some cross-sectional studies and meta-analyses, there were limitations in showing causality. Moreover, a serial follow-up of symptomatic changes, lung function decline and COPD exacerbation rates according to TB history has never been performed.
This study aimed to investigate the severity and clinical outcomes of COPD in patients with history of TB compared with patients with no such history who were followed up for 3 years.
METHODS

Data collection
We analysed data from the Korean COPD Subtype Study (KOCOSS) cohort collected from 45 study centres throughout Korea. 19 Recruitment, enrolment and measurement occurred between December 2011 and January 2017. Enrolment criteria for the KOCOSS were Korean adults ≥40 years old with a post-bronchodilator forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) value <0.7 at any clinical visit. The history of treatment for COPD was overlooked for inclusion. The exclusion criteria were inability to perform the pulmonary function test, use of systemic steroids because of other underlying diseases, and inability to communicate with clinicians. Demographic data, smoking history and status and co-morbidities were assessed at the first visit. TB history was also included in the questionnaire. The question specific for TB history was: 'Have you ever been diagnosed with TB?' Prior TB group was defined based on this questionnaire regardless of the chest X-ray (CXR) findings. All data were collected by trained nurses, and patients attended follow-up visits at regular 6-month intervals.
This KOCOSS cohort is still ongoing; for the followup analysis, we included all the patients who have a full data set with at least 3 years of follow-up. The study protocol was approved by the institutional review board at each centre. All patients provided written informed consent for participation in the study.
CAT and SGRQ scores
The COPD assessment test (CAT) score 20 and St George's Respiratory Questionnaire for COPD (SGRQc) score 21 were used to assess symptoms, quality of life and health status in patients with COPD.
Exacerbation definition
Exacerbations were defined as the worsening of any respiratory symptom, such as increased sputum volume, purulence or increased dyspnoea, which required treatment with systemic corticosteroids, antibiotics or both. Exacerbation history in the previous 12 months was assessed at the first visit and at the 1-, 2-and 3-year follow-up visits based on a self-reported survey. Severe exacerbation was defined as the exacerbation requiring hospital admission including general ward, emergency room or intensive care unit (ICU). The prevalences of exacerbation and severe exacerbation were calculated according to the proportion of subjects among the total number of subjects who had experienced at least one exacerbation event or severe exacerbation event during the last year prior to enrolment.
Lung function and CXR
Pulmonary function tests including FVC, postbronchodilator FEV 1 , post-bronchodilator FEV 1 /FVC, forced expiratory flow during the middle half of the FVC (FEF 25-75% ), diffusing capacity of the lung for carbon monoxide (DL CO ) and DL CO /alveolar volume (VA) were conducted at 1-year intervals for 3 years. CXR was interpreted by the radiology department affiliated with each institute. A TB lesion was defined as a lesion with fibrosis (linear or reticulofibrotic opacities) located in the upper lung, as previously reported. 22 
Statistical analysis
For continuous variables, descriptive statistics are reported as means with SD, and for categorical variables, as the number of patients per category and the frequency of responses. Comparisons of continuous variables were analysed using a two-sample t-test and analysis of variance (ANOVA); chi-square tests were used for comparisons of categorical variables. Comparisons of symptom scores and FEV 1 changes were assessed with a repeated ANOVA to compare the prognoses and changes in these variables during the followup period. Differences were considered statistically significant at P < 0.05.
RESULTS
Clinical characteristics according to TB history
Among the 1839 patients enrolled, 1784 patients were analysed in this study. Among them, 1316 patients had no TB history (non-TB group), whereas 468 patients had a TB history (prior TB group). A subset of the patients were followed up serially over 3 years as regards to symptoms, lung function and exacerbation history ( Fig. 1) .
Age, male sex prevalence, weight and the prevalence of underlying disease were not different between the prior TB group and non-TB group. Height in the prior TB group was slightly taller than that in the non-TB group (P = 0.022). Current smokers were more prevalent in the non-TB group (32.2%) than in the prior TB group (22.9%) (P < 0.001) ( Table 1) . In a multivariate analysis, height (OR: 1.024; 95% CI: 1.003-1.045; P = 0.027) and current smoker status (OR: 0.592; 95% CI: 0.440-0.780; P < 0.001) remained significant factors associated with TB history (Table 2) .
Symptoms, lung function and exacerbation rate at first visit for enrolment according to TB history Subjects in the prior TB group complained of more severe symptoms at the first visit for enrolment and had a significantly higher CAT score and total SGRQc score than subjects in the non-TB group (Table 3) . Lung function was poorer, with FVC, FEV 1 , FEV 1 /FVC, FEF 25-75% and DL CO significantly lower in the prior TB group than in the non-TB group (Table 3) . The prevalence of subjects who experienced more than one exacerbation event over the last 1 year and the prevalence of severe exacerbation requiring admission to the emergency room were significantly higher in the prior TB group than that in the non-TB group (Table 3) . When adjusted with significant baseline characteristics (height and current smoking status), prior TB history was a significant risk factor associated with total exacerbation (OR: 1.336; 95% CI: 1.020-1.750; P = 0.035) and severe exacerbation (OR: 2.175; 95% CI: 1.109-4.263; P = 0.024, missing data was 163).
Changes in symptoms and quality of life according to TB history
Among all the patients enrolled in this study (n = 1784), 318 patients (17.8%) and 295 patients (16.5%) completed serial follow-up visits for the CAT score and total SGRQc score, respectively, over 3 years. Among the 318 patients with 3 years dataset for the CAT score, 106 and 212 patients were from the prior TB group and non-TB group, respectively. The CAT score in the prior TB group had improved after 1 year (15.0 AE 0.7), 2 years (14.4 AE 0.7) and 3 years (13.7 AE 0.7) compared with baseline (15.6 AE 0.7); those in the non-TB group also improved after 1 year (14.4 AE 0.5), 2 years (13.9 AE 0.5) and 3 years (13.6 AE 0.5) compared with baseline (15.1 AE 0.5). Although the difference in CAT scores between the two groups remained over the 3 years, there was no significant difference in the changes between them (P for the changes between the groups = 0.880) ( Fig. 2A) . Similar to the CAT score, the total SGRQc score in the prior TB group at baseline (36.5 AE 2.1) was significantly higher than that in the non-TB group (29.5 AE 1.3). This trend of a higher total SGRQc score in the prior TB group remained over the 3 years. However, there was no significant difference in SGRQc score changes between the groups (P for changes between the groups = 0.228) (Fig. 2B) .
Changes in lung function according to TB history
Among the 182 patients who underwent lung function follow-up visits at 1-year intervals for 3 years, 42 and 140 patients were classified into the prior TB group and non-TB group, respectively. The absolute FEV 1 (L) in the prior TB group at baseline (1.53 AE 0.09) worsen after 1 year (1.54 AE 0.10), 2 years (1.53 AE 0.10) and 3 years (1.47 AE 0.10) which represents a rapid decline of −20.6 mL/year. In contrast, the absolute FEV 1 in the non-TB group improved after 1 year (1.63 AE 0.4), 2 years (1.61 AE 0.04) and 3 years (1.59 AE 0.04) compared with baseline (1.57 AE 0.04) which represents an improvement of +4.7 mL/year. Although the absolute FEV 1 worsen in the prior TB group and improved in the non-TB group, there was no significant difference between the two groups (P for changes between the groups = 0.276) (Fig. 2C) .
The predicted FEV 1 in the prior TB group was aggravated as time elapsed (average = −0.57%/year), whereas that in the non-TB group was improved (average = +0.93%/year). However, there was no statistically significant difference between them (P for changes between the groups = 0.076) (Fig. 2D) .
Changes in exacerbation prevalence according to TB history
Among the 256 patients followed up for exacerbation history for 3 years, 73 and 183 patients were classified into the prior TB group and non-TB group, respectively. The prevalence of subjects who experienced a COPD exacerbation over the last 1 year in the prior TB group (20.5%) at baseline was slightly higher than that in the non-TB group (18.0%) and increased and remained higher after 3 years (27.4% vs 23.5%, respectively). However, there was no statistically significant difference between the two groups. Moreover, changes in exacerbation prevalence over the 3 years were not significantly different between the two groups (P for changes between the groups = 0.965) (Fig. S1 , Supplementary Information).
Comparisons of lung function in prior TB group between those with and without lung lesions
We divided the prior TB group according to the presence of lung lesions on CXR. Ninety-seven patients demonstrated no lesion on CXR, whereas 115 patients had a definite lesion on CXR. Compared with the non-TB group, FEV 1 was lower in prior TB group subjects with and without lesions. Moreover, lung function was similar in the prior TB group between subjects with lesions on CXR and those without (Fig. S2 , Supplementary Information).
DISCUSSION
We showed that COPD patients with a history of TB had more severe symptoms, poorer lung function and more frequent exacerbations, and that these differences were sustained for several years compared with those with no TB history. Although there are many studies concerning TB as a cause, 23 co-morbidity 16, 24 and aggravating factor for COPD 25 as mentioned in the 2017 GOLD (Global Initiative for Obstructive Lung Disease) guidelines, 26 studies comparing the severity and clinical outcomes of COPD serially according to TB history are extremely rare. TB can lead to remodelling of the lung parenchyma including cavitation, fibrosis, bronchiectasis and lung destruction. 27 Many studies suggested that these structural damages to the lung in TB patients were an important factor in the development of COPD. [28] [29] [30] Tang et al. showed that the impaired cellular immunity in COPD patients can be more serious when it is complicated by TB. 31 However, the serial effects of TB on the severity and clinical outcomes of COPD over several years had never been studied before now.
Although statistically significant results were not obtained because of the limited number of patients available for serial follow-up, we found that lung function decline in patients with a TB history may be faster than in patients with no TB history. This result suggests that subjects with a TB history have not only poor lung function temporarily, but also a poor lung function outcome. There have been some reports that described the adverse effect of TB on lung function. 32 A recent study demonstrated that adverse effects of TB on lung function (FEV 1 and PaCO 2 ) were also applicable to COPD patients. 25 Another interesting finding in this study is that prior TB group subjects without lung lesions on CXR showed similar lung function to those with lung lesions on CXR. Jung et al. 18 revealed that subjects without lesions on CXR showed impaired pulmonary function and respiratory symptoms along with subjects with lesions. TB sequelae or microscopic lesions might not always be detectable by CXR and might need computed tomography (CT) scans or further analysis, therefore a prior diagnosis of TB should be considered as a risk factor, even when patients do not present with a lesion on CXR.
Patients with a TB history showed a significantly lower prevalence of current smoking than did patients with no TB history. Moreover, they had lighter smoking histories. The patients' TB history might have played a role in this observation.
TB is a treatable and curable disease. However, TB is one of the world's largest causes of morbidity and mortality. All patients with a history of TB should be educated by clinicians, especially in countries where TB is prevalent, to take particular care of their lungs, including stopping smoking and undergoing close monitoring of lung function. Korea is a country with an intermediate TB burden. This study thus included a large portion of subjects with a prior TB history among COPD patients. Longer term follow-up data from this study will show more powerful results concerning clinical outcomes and prognosis.
There are some limitations to this study. First, this study included limited information concerning TB, for example, the age at TB onset, treatment history for TB, TB drug susceptibility or the types and results of treatment. Second, the classification of CXR lesions is not fully consistent because it was provided by different institutions. Third, only a small number of patients completed the entire 3-year follow-up study which limited the validity of results on the longitudinal change in symptoms, lung function and exacerbations. Fourth, the information concerning TB history and exacerbation was obtained based on the self-reported questionnaire. Lastly, the treatment history for COPD varied at enrolment. However, the prevalence of treatment-naïve patient was small (<10%) and was not different according to the group. Further long-term and larger cohort studies will be helpful to compare the severity and clinical outcomes of COPD according to TB history.
In conclusion, COPD patients with a TB history showed more severe symptoms, poorer lung function and more frequent exacerbations. In addition, the 3 year follow-up study showed that these differences were sustained compared with subjects with no TB history. Clinicians should be aware such observations for COPD patients with a concurrent TB history.
